Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin effects on gut microbiota in newly diagnosed type 2 diabetes in China
ChiCTR-IPR-17013314Phase 4Recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alogliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Peking University Shenzhen Hospital. Primary endpoints: intestinal flora and HbA1c. Started Sep 2017; status: recruiting.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-17013314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013314.